Medicaid is pressing state governments to tighten oversight of autism spectrum disorder therapies due to a dramatic five-fold increase in spending since 2021. This surge in expenditure, which far outpaces new diagnoses, has raised serious red flags concerning potential over-prescription of treatments and instances of fraudulent billing within the crucial health program, prompting a call for enhanced state-level monitoring.
